Artiva grants director Stoppel 16,250 options

Artiva Biotherapeutics director Laura Stoppel was granted 16,250 stock options that vest by the 2027 annual meeting and are held for the benefit of RA Capital-managed funds.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 16,250 Director Stock Options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036.

The options will vest in full on the earlier of September 10, 2027 or the date of Artiva’s 2027 annual stockholder meeting. According to the disclosure, Stoppel holds this option for the benefit of funds and an account managed by RA Capital Management, L.P. and disclaims beneficial ownership of the option and underlying common stock. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 16,250 shares

Grant/Award 1 txn

Insider Stoppel Laura

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1, F2	16,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 16,250 contracts (Direct)

Footnotes (2)

1. F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
2. F2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

Key Figures

Director Stock Options granted: 16,250 options Exercise price: $10.42 per share Underlying common shares: 16,250 shares +2 more

5 metrics

Director Stock Options granted 16,250 options Grant to director Laura Stoppel on September 10, 2026

Exercise price $10.42 per share Exercise price of Director Stock Options granted September 10, 2026

Underlying common shares 16,250 shares Shares of Artiva common stock underlying the Director Stock Options

Option expiration date September 9, 2036 Expiration of the Director Stock Options granted to Laura Stoppel

Latest vesting date September 10, 2027 Options vest on the earlier of this date or the 2027 annual meeting

Key Terms

Director Stock Option, beneficial ownership, separately managed account, advisory fees

4 terms

Director Stock Option financial

"The shares subject to the option will vest in full on the earlier"

beneficial ownership financial

"The Reporting Person therefore disclaims beneficial ownership of the stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

separately managed account financial

"and a separately managed account (the "Account"). The Reporting Person"

A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.

advisory fees financial

"which will offset advisory fees owed by the Fund, the Nexus"

Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV report for director Laura Stoppel?

Artiva Biotherapeutics reported that director Laura Stoppel received a grant of 16,250 Director Stock Options on September 10, 2026, covering an equal number of shares of Artiva common stock at an exercise price of $10.42 per share.

What are the vesting terms of the new stock options reported for ARTV?

The options granted to director Laura Stoppel will vest in full on the earlier of September 10, 2027 or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, after which they become exercisable subject to their other terms.

What is the exercise price and expiration date of the ARTV options granted?

The Director Stock Options granted on September 10, 2026 have an exercise price of $10.42 per share and an expiration date of September 9, 2036, giving a 10-year term from the grant date.

Does Laura Stoppel personally benefit from the ARTV stock option grant?

The filing states that Laura Stoppel holds the option for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund III and a separately managed account, must turn over any net cash or stock to the Adviser, and disclaims beneficial ownership of the option and underlying shares.

Is the ARTV option grant to Laura Stoppel under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, and there is no footnote stating that the option grant was made pursuant to a Rule 10b5-1 trading plan.

How many derivative securities does Laura Stoppel hold in ARTV after this grant?

After the reported grant, the total reported derivative holdings from this option are 16,250 Director Stock Options. The filing notes these are held for the benefit of RA Capital-managed funds and that beneficial ownership is disclaimed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:06 PM Accepted by SEC EDGAR 09/14/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stoppel Laura

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.42	09/10/2026		A		16,250		(1)	09/09/2036	Common Stock	16,250	$0	16,250	D(2)

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)